Product image of Insulin Lispro Sanofi (Insulin Lispro) supplied by GNH India

Insulin Lispro Sanofi

Active Ingredient:
Insulin Lispro
Origin:
EU

Insulin Lispro Sanofi (Insulin Lispro)

Insulin lispro, the active ingredient in Insulin Lispro Sanofi, is an insulin analog presented as a clear solution for injection for subcutaneous use. It is used to lower blood glucose levels in patients with type 1 or type 2 diabetes mellitus, providing rapid‑acting insulin coverage around meals.

GNH India supplies Insulin Lispro Sanofi as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide while ensuring quality and regulatory compliance across markets.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insulin lispro is a rapid‑acting insulin analog that acts on post‑prandial glucose control in diabetes mellitus.

  • Type 1 diabetes mellitus: provides rapid‑acting insulin to control post‑prandial glucose spikes.
  • Type 2 diabetes mellitus: used as part of basal‑bolus regimens to improve overall glycemic control.

How It Works

  • Insulin lispro binds to the insulin receptor on peripheral tissues, rapidly stimulating glucose uptake in muscle and adipose cells while suppressing hepatic glucose production. Its structural modification accelerates dissociation of hexamers, resulting in a faster onset of action compared with regular human insulin, thereby lowering blood glucose levels promptly after injection.

Side Effects

Common side effects of rapid‑acting insulin analogues include:

Common Side Effects

  • Hypoglycemia: low blood sugar episodes, especially if meals are missed or delayed.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: modest increase due to improved glucose utilization.
  • Lipodystrophy: localized fat tissue changes from repeated injections.
  • Nausea or headache: occasional transient symptoms.

Serious or Rare Side Effects

  • Severe hypoglycemia: may cause seizures, loss of consciousness, or require emergency treatment.
  • Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.
  • Edema: swelling of extremities due to fluid retention.
  • Hypokalemia: low potassium levels, particularly with high insulin doses.
  • Acute insulin resistance: sudden loss of insulin effectiveness.

Precautions & Warnings

When using Insulin Lispro Sanofi, consider the following precautions:

  • Dose adjustment: regularly monitor blood glucose and adjust dose accordingly.
  • Renal impairment: may require dose modification due to altered insulin clearance.
  • Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
  • Hypoglycemia risk: educate patients on recognizing and treating low blood sugar promptly.
  • Drug interactions: avoid concurrent use with other rapid‑acting insulins without medical supervision.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Avoid Interactions

Insulin lispro may interact with several medications that affect glucose metabolism.

Major Interactions (Avoid)

  • Concurrent use of other rapid‑acting insulins: increased risk of severe hypoglycemia.
  • Beta‑blockers: may mask typical hypoglycemia symptoms such as tachycardia.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or meglitinides: additive glucose‑lowering effect, monitor for hypoglycemia.
  • ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering action.
  • Thiazide diuretics: can raise blood glucose levels, requiring dose adjustment.
  • Corticosteroids: may increase insulin requirements due to hyperglycemic effect.

Frequently Asked Questions

Insulin Lispro Sanofi is a rapid‑acting insulin analog indicated for the treatment of type 1 and type 2 diabetes mellitus. It helps control post‑prandial blood glucose spikes by providing quick insulin action after subcutaneous injection.

Insulin lispro binds to insulin receptors on muscle and fat cells, rapidly stimulating glucose uptake and inhibiting hepatic glucose production. Its modified structure allows faster dissociation from hexamers, resulting in a quicker onset of action compared with regular human insulin.

The dose of Insulin Lispro Sanofi is individualized and set by a qualified prescriber based on the patient’s blood glucose monitoring, meal patterns, and overall treatment plan. No fixed dosing regimen is provided in the product information.

The safety of insulin lispro in pregnancy or while breastfeeding has not been definitively established. It should be used only if the potential benefits to the mother outweigh any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Insulin lispro has a faster onset and shorter duration of action than regular human insulin, similar to other rapid‑acting analogues such as insulin aspart and insulin glulisine. It offers comparable efficacy in post‑prandial glucose control, with a low risk of intra‑patient variability.

Insulin Lispro Sanofi should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial. Once in use, the vial may be kept at room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

The product is supplied as a clear solution for subcutaneous injection. It is typically injected into the abdomen, thigh, or upper arm using a sterile needle or an insulin pen, according to the prescriber’s instructions and timing relative to meals.

The most serious risks include severe hypoglycemia, which can lead to seizures, loss of consciousness, or death, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing symptoms and have a plan for immediate treatment.

Insulin Lispro Sanofi should not be used by individuals with a known hypersensitivity to insulin lispro or any of the product’s excipients. It is also contraindicated in patients with severe hypoglycemia unawareness unless closely monitored by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Lispro

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT